The biomarker discovery outsourcing service market is estimated to be valued at USD 13.3 billion in 2024. The biomarker discovery outsourcing service market is predicted to rise at a CAGR of 12.2% from 2024 to 2034. The global biomarker discovery outsourcing service market is anticipated to reach USD 41.4 billion by 2034.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | USD 13.3 billion |
| Projected Market Value in 2034 | USD 41.4 billion |
| Value-based CAGR from 2024 to 2034 | 12.2% |
The increasing research and development activities in the biotechnology and pharmaceutical industries are expected to drive the biomarker discovery outsourcing service market. Outsourcing services are in demand as demand for biomarkers is increasing in the diagnosis and treatment monitoring of various diseases.
With the increasing burden of various chronic diseases such as cancer, neurological disorders, and cardiovascular disorders, the demand for various biomarkers has increased significantly.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
From 2019 to 2023, the biomarker discovery outsourcing service market experienced a CAGR of 15.6%. Increasing advances in technology like bioinformatics, genomics and proteomics, the demand for biomarker discovery outsourcing service are expected to rise.
The biomarkers are primarily utilised in drug development and clinical research applications, the market for outsourcing services is expected to rise. The rising integration of biomarkers in precision medicine drive the demand for outsourcing services tailored to personalized treatment strategies.
The biomarker discovery outsourcing service market is poised for continued expansion with Incresed technological advances and expansion in new therapeutic area. Projections indicate that the global biomarker discovery outsourcing service market will experience a CAGR of 12.2% from 2024 to 2034.
| Historical CAGR from 2019 to 2023 | 15.6% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 12.2% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The provided table highlights the top five countries in terms of revenue, with the South Korea and Japan leading the list. Incresed regulatory support and funding in biopharmaceutical in South Korea boost the market growth. Biomarker discovery outsourcing service market in Japan is mainly driven by advances in healthcare industry.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 12.4% |
| The United Kingdom | 13.3% |
| China | 12.9% |
| Japan | 13.9% |
| South Korea | 14.0% |
The biomarker discovery outsourcing service market in the United States is expected to expand with a CAGR of 12.4% from 2024 to 2034. Increasing investment in research and development in biopharmaceutical industry driving the market growth.
With the increasing demand for personalized medicines and innovative healthcare solutions, the demand for biomarker discovery outsourcing service is expected to rise in the country.
The increasing advanced in next generation sequencing and bioinformatics accelerated biomarker discovery, providing opportunities for outsourcing services to provide cutting edge solutions to their clients.
The biomarker discovery outsourcing service market in the United Kingdom is expected to expand with a CAGR of 13.3% from 2024 to 2034. The growth of the market in the country is attributed to the presence of robust biotechnology industry.
Increasing government support and funding for biomedical research initiatives drive the demand for outsourcing services. The presence of advanced healthcare infrastructure and increased access to cutting edge technology to boost the market for biomarker discovery outsourcing service in the United Kingdom.
The biomarker discovery outsourcing service market in China is expected to expand with a CAGR of 12.9% from 2024 to 2034. The increasing focus on precision medicines in China contributed to the market growth.
The presence to large patient population and availability of diverse genetic data enhances the quality and relevance of biomarker discovery services in China.
With increasing healthcare innovation and growing demand for customized medicines is increasing, the biomarker discovery outsourcing service market in china will continue to rise during the forecast period.
The biomarker discovery outsourcing service market in Japan is expected to expand with a CAGR of 13.9% from 2024 to 2034.
With the presence of advanced healthcare infrastructure and strong biotechnology sector in Japan, the demand for biomarker discovery outsourcing services for drug discovery and development are expected to rise in the country.
The growing aging population and increased healthcare challenges and various age related disorders such as neurological diseases, cardiovascular disorders, driving the market demand.
Increasing government support and investment in biopharmaceutical industry and Incresed research and development activity are expected to drive the marker discovery outsourcing service market in South Korea.
With the increasing demand for innovative healthcare solutions and precision medicine in South Korea the market for biomarker discovery outsourcing services is expected to rise in the country.
The biomarker discovery outsourcing service market in South Korea is expected to expand with a CAGR of 14% from 2024 to 2034.
The below segment shows the leading segment. Surrogate end-point segment is to rise at a CAGR of 12.0% from 2024 to 2034.Based on type, the genomic biomarker services segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 11.8% from 2024 to 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Surrogate End-point | 12.0% |
| Genomic Biomarker Services | 11.8% |
Based on the type, the biomarker discovery outsourcing service market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints and other types.
Among these types surrogate end-point segment is anticipated to rise at a CAGR of 12.0% from 2024 to 2034. The demand for surrogate endpoint is high as they provide shorter and cost effective trials.
Surrogate endpoints open up new possibilities for innovation in therapeutic development, as they make it possible to access new treatment more quickly.
Based on the service, the biomarker discovery outsourcing service market is segmented into genomic biomarker services, proteomics biomarker services, bioinformatics biomarker services and other biomarker services. Among these services, genomic biomarker services segment is anticipated to thrive at a CAGR of 11.8 % from 2024 to 2034
Genomic biomarkers are used in early diagnostic and tracking of genetic diseases, infectious diseases and inherited disorders. The increasing reliance on precision medicines driving the high demand for genomic biomarker services.
The market players operation in biomarker discovery outsourcing service market are concentrating on partnership, collaboration, acquisition to gain competitive edge in the market. The leading players are investing in research and development and expansion of service offerings.
Market players are increasing range of service to provide comprehensive biomarker services catering to unique demand of various biotechnology and pharmaceutical clients.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | USD 31.1 billion |
| Projected Market Valuation in 2034 | USD 41.4 billion |
| Value-based CAGR 2024 to 2034 | 12.2% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East and Africa |
| Key Market Segments Covered | Type, Service, Therapeutic Area, End User, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | Bio-Rad Laboratories, Inc.; Parexel International (MA) Corporation; Svar Life Science; Sino Biological Inc.; ICON plc.; Integrated DNA Technologies Inc.; Almac Group Limited; REPROCELL Inc.; Frontage Labs; Biomcare ApS; Crown Bioscience |
As of 2024, the market for biomarker discovery outsourcing service is expected to be valued at USD 31.1 billion.
By 2034, the market value of biomarker discovery outsourcing service is expected to reach USD 41.4 billion.
From 2024 to 2034, the biomarker discovery outsourcing service market is expected to flourish at a CAGR of 12.2%
Surrogate end-point segment is expected to rise at a CAGR of 12% from 2024 to 2034.
South Korea is likely the top-performing market, with a CAGR of 14%.
| Estimated Size, 2024 | USD 585.0 million |
|---|---|
| Projected Size, 2034 | USD 1,631.4 million |
| Value-based CAGR (2024 to 2034) | 10.8% |
| Market Value for 2024 | USD 1,541.2 million |
|---|---|
| Market Value for 2034 | USD 3,031.8 million |
| Market CAGR (2024 to 2034) | 7% |
| Market Estimated Size in 2023 | USD 1,950 million |
|---|---|
| Projected Market Value in 2033 | USD 3,206.73 million |
| Value-based CAGR from 2023 to 2033 | 5.1% |
| Market Size (2023) | USD 8 billion |
|---|---|
| Market Size (2033) | USD 12.5 billion |
| Market CAGR (2023 to 2033) | 4.6% |
Explore Healthcare Services Insights
View Reports
Biomarker Discovery Outsourcing Service Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
